Differential effects in cardiovascular markers between high-dose angiotensin II receptor blocker monotherapy and combination therapy of ARB with calcium channel blocker in hypertension (DEAR Trial)

International Journal of Hypertension

Volumn 2011, Issue , 2011, Pages

  Kinouchi, Kenichiro ^a   Ichihara, Atsuhiro ^a   Bokuda, Kanako ^a   Kurosawa, Hideaki ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; AZELNIDIPINE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATININE; CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLMESARTAN; POTASSIUM; RENIN; TRIACYLGLYCEROL;

ADULT; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIO ANKLE VASCULAR INDEX; CARDIOVASCULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 84868295034     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.4061/2011/284823     Document Type: Article

References (30)

1. Laurent S., Boutouyrie P., Asmar R., Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001 37 5 1236 1241 2-s2.0-0035714567 (Pubitemid 34163575)
2. Safar M. E., Systolic blood pressure, pulse pressure and arterial stiffness as cardiovascular risk factors. Current Opinion in Nephrology and Hypertension 2001 10 2 257 261 2-s2.0-0035107919 10.1097/00041552-200103000- 00015 (Pubitemid 32221769)
3. Williams B., Lacy P., Thom S., Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006 113 9 1213 1225
4. Ichihara A., Yamashita N., Takemitsu T., Cardio-ankle vascular index and ankle pulse wave velocity as a marker of arterial fibrosis in kidney failure treated by hemodialysis. American Journal of Kidney Diseases 2008 52 5 947 955 2-s2.0-54149110158 10.1053/j.ajkd.2008.06.007
5. Mahmud A., Feely J., Effect of angiotensin II receptor blockade on arterial stiffness: beyond blood pressure reduction. American Journal of Hypertension 2002 15 12 1092 1095 2-s2.0-0036892857 10.1016/S0895-7061(02)02982- 5 (Pubitemid 35397544)
6. Bokuda K., Ichihara A., Sakoda M., Mito A., Kinouchi K., Itoh H., Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome. Vascular Health and Risk Management 2010 6 571 578
7. Kinouchi K., Ichihara A., Sakoda M., Kurauchi-Mito A., Itoh H., Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. Hypertension Research 2009 32 12 1143 1147 2-s2.0-73849090805 10.1038/hr.2009.162
8. Kinouchi K., Ichihara A., atzichi@sc.itc.keio.ac.jp Sakoda M., Kurauchi-Mito A., Murohashi-Bokuda K., Itoh H., Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients. Kidney and Blood Pressure Research 2010 33 4 304 312 10.1159/000316724
9. Miyashita Y., Saiki A., Endo K., Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. Journal of Atherosclerosis and Thrombosis 2009 16 5 621 626 2-s2.0-73249144824
10. Miyoshi T., miyoshit@cc.okayama-u.ac.jp Doi M., Hirohata S., Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart and Vessels. In press 10.1007/s00380-010-0060-x
11. Ichihara A., Kaneshiro Y., Takemitsu T., Sakoda M., Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. Journal of Human Hypertension 2006 20 10 787 794 2-s2.0-33748928162 10.1038/sj.jhh.1002067 (Pubitemid 44430678)
12. Li J. M., Iwai M., Cui T. X., Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells. Molecular Pharmacology 2005 67 5 1666 1673 2-s2.0-17844364587 10.1124/mol.104.008144 (Pubitemid 40594166)
13. Jinno T., Iwai M., Li Z., Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004 43 2 263 269 2-s2.0-0842311007 10.1161/01.HYP.0000113627.08110.6f (Pubitemid 38174185)
14. Inaba S., Iwai M., Tomono Y., Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists. American Journal of Hypertension 2009 22 2 145 150 2-s2.0-58549083347 10.1038/ajh.2008.344
15. Matsui Y., yoshio@jichi.ac.jp Eguchi K., O'Rourke M. F., Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009 54 4 716 723 10.1161/HYPERTENSIONAHA. 109.131466
16. Suzuki J., Iwai M., Li Z., Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. Journal of Hypertension 2005 23 7 1383 1389 2-s2.0-21644472752 (Pubitemid 40933959)
17. Tada T., Nawata J., Wang H., Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension. Cardiovascular Research 2008 80 3 346 353 2-s2.0-56549110280 10.1093/cvr/cvn211
18. Cheng X. W., Okumura K., Kuzuya M., Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. Journal of Cardiovascular Pharmacology 2009 54 1 47 56 2-s2.0-68249162096 10.1097/FJC.0b013e3181ab371d
19. Kim-Mitsuyama S., Izumi Y., Izumiya Y., Yoshida K., Yoshiyama M., Iwao H., Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model. Hypertension Research 2004 27 10 771 779 2-s2.0-11044233241 10.1291/hypres.27. 771 (Pubitemid 40045517)
20. Lu H., Kanazawa M., Ishida A., Combination of chronic exercise and antihypertensive therapy enhances renoprotective effects in rats with renal ablation. American Journal of Hypertension 2009 22 10 1101 1106 2-s2.0-70349470963 10.1038/ajh.2009.148
21. Tanifuji C., Suzuki Y., Geot W. M., Horikoshi S., Takahashi H., Tomino Y., Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys. Kidney and Blood Pressure Research 2009 32 4 239 249 2-s2.0-70049088322 10.1159/000238821
22. Willum-Hansen T., Staessen J. A., Torp-Pedersen C., Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006 113 5 664 670 2-s2.0-33644863316 10.1161/CIRCULATIONAHA.105.579342
23. Dawson A., Davies J. I., Morris A. D., Struthers A. D., B-type natriuretic peptide is associated with both augmentation index and left ventricular mass in diabetic patients without heart failure. American Journal of Hypertension 2005 18 12 1586 1591 2-s2.0-29144460629 10.1016/j.amjhyper.2005. 06.016 (Pubitemid 41814680)
24. Sakuragi S., Maruo T., Taniguchi M., Radial augmentation index associated with increase in B-type natriuretic peptide in patients with hypertension. International Journal of Cardiology 2008 130 3 414 419 2-s2.0-55549136413 10.1016/j.ijcard.2007.08.129
25. Asmar R., Gosse P., Topouchian J., N'tela G., Dudley A., Shepherd G. L., Effects of telmisartan on arterial stiffness in type 2 diabetes patients with esssential hypertension. Journal of the Renin-Angiotensin-Aldosterone System 2002 3 3 176 180 2-s2.0-0036756245 (Pubitemid 35345616)
26. Doi M., Miyoshi T., Hirohata S., Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients. American Journal of the Medical Sciences 2010 339 5 433 439 2-s2.0-77952277125 10.1097/MAJ.0b013e3181d658c4
27. Ishimitsu T., Numabe A., Masuda T., Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertension Research 2009 32 11 962 968 2-s2.0-71049182208 10.1038/hr.2009.133
28. Nada T., Nomura M., nomura@ias.tokushima-u.ac.jp Koshiba K., Kawano T., Mikawa J., Ito S., Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity. Arzneimittelforschung 2007 57 11 698 704 (Pubitemid 350239806)
29. Ohmura C., Watada H., Shimizu T., Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure. Endocrine Journal 2007 54 5 805 811 2-s2.0-40649083850 10.1507/endocrj.K07-063 (Pubitemid 351377761)
30. Ogihara T., Saruta T., Shimada K., Kuramoto K., A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study. Hypertension Research 2009 32 12 1148 1154 2-s2.0-73849138948 10.1038/hr.2009.163